STS releases first publicly accessible report of outcomes from lung cancer surgery

NewsGuard 100/100 Score

The Society of Thoracic Surgeons (STS) has released the first publicly accessible national report of outcomes from lobectomy, a lung cancer procedure that removes a portion of the lung. The surgical outcomes data are from the Society's General Thoracic Surgery Database (GTSD), one of three components in the world-renowned STS National Database, which is widely considered the gold standard for medical specialty outcomes databases.

"Voluntary public reporting of our outcomes is one of the most important ways that cardiothoracic surgeons have distinguished themselves among all other health care providers," said David M. Shahian, MD, of Massachusetts General Hospital in Boston and Chair of the STS Council on Quality, Research, and Patient Safety. "We are one of the very few specialties that has affirmed the ethical responsibility of health care professionals to provide results to patients."

General thoracic surgeons specialize in diseases of the lungs, the esophagus, and the mediastinum (the area between the lungs). They perform operations for cancer and benign conditions, as well as lung transplants. The launch of GTSD public reporting demonstrates the commitment of these surgeons to transparency, accountability, and quality improvement in health care delivery.

Adult Cardiac Surgery Database (ACSD) participants have been publicly reporting outcomes since 2010, with approximately 56% of ACSD participants enrolled. Public reporting became available in early 2015 for Congenital Heart Surgery Database (CHSD) participants, with 59% now sharing their outcomes.

"Public reporting of surgical outcomes is becoming a routine expectation for patients, payers, and other stakeholders," said Benjamin D. Kozower, MD, of Washington University in St. Louis and Chair of the GTSD Task Force. "STS has done a tremendous job of establishing a transparent and sound methodology for public reporting in ACSD and CHSD. Thoracic surgery is very excited to join this effort."

The GTSD is the largest and most robust clinical thoracic surgical database in North America. The GTSD contains more than 480,000 general thoracic surgery procedure records and currently has more than 900 participating surgeons.

For the first stage of GTSD public reporting, a list of all active participating institutions in the GTSD as of October 31, 2016, was published on the STS website; individual surgeons at each institution also were named. Additionally, STS has published the discharge mortality and median postoperative length of stay for lobectomy for all GTSD participants as a group and compared those numbers to corresponding figures from the National Inpatient Sample, which is the largest, all-payer inpatient database available in the United States.

"The general thoracic programs that participate in the STS National Database generally represent the very best of their type in the US and, on average, have better results," said Dr. Shahian. "Participation in the Database and public reporting provides patients and their families with meaningful information. Patients have a right to make informed decisions about choice of treatment and providers, and public reporting is one way to facilitate this."

Making it easier for patients to understand the results of individual STS Database participants, STS uses a star ratings system to indicate performance. Participants receive a 3-star, 2-star, or 1-star rating. "Three-star programs perform better than average, an STS rating that is very difficult to achieve. Patients should understand that an STS 2-star program [average, or 'as expected'], is also performing quite well," said Dr. Shahian. "In fact, our studies suggest that the results of an 'average' STS GTSD participant are likely far superior to those of non-STS GTSD programs. Publicly reported outcomes are just one piece of information that patients should incorporate into their decision-making regarding the choice of a provider." Dr. Shahian suggests that patients also consider the recommendations of their primary care physicians, the training, experience, and procedure volumes of potential providers, the reputation of the surgical group and hospital, and the quality of the patient's personal interactions with the providers and their staff.

Future Plans for GTSD Public Reporting
Later this year, participant-level outcomes for lobectomy are expected to be publicly reported with comparisons to overall STS and national outcomes. Discharge mortality, median postoperative length of stay, and a two-domain lobectomy composite measure (including risk-adjusted mortality and major complications) will be reported for consenting programs.

"We strive for 100% participation in our public reporting program. This will send a very powerful message about our commitment to quality," explained Dr. Shahian. "Just as we are expanding public reporting into general thoracic surgery, we are also broadening the portfolio of measures that we report. Ultimately, this should include mortality and complication composite metrics for all our most commonly performed procedures, and in the future, readmissions, failure to rescue, patient-reported outcomes, and patient satisfaction."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels